Beam Therapeutics Inc. (BEAM): Total Assets
$1.48B
As of 2025-12-31
$1.39B
As of 2026-06-30
+3.4%
3-year compound annual growth
+26.8%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.48B | +34.2% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $1.10B | -24.4% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $1.46B | +8.8% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $1.34B | -9.0% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $1.47B | +226.4% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $451.68M | +189.4% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $156.10M | n/a | 2021-03-15, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $1.48B | +34.2% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $448.66M | +2.3% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $20.23M | -81.5% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $1.12B | -18.7% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $453.03M | -2.8% |
| Agenus Inc (AGEN) | 2025-12-31 | $226.80M | +0.2% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $501.90M | +31.1% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $245.96M | -13.0% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $223.70M | -36.7% |
Compare BEAM, GLUE, ATRA, DNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗